Research advances of sodium-glucose cotransporter 2 inhibitors for the treatment of obstructive sleep apnea

Obstructive Sleep apnea(OSA)is a common sleep-breathing disorder characterized by recurrent upper airway obstruction during sleep, resulting in intermittent hypoxia and sleep fragmentation. Continuous positive airway pressure is the first-line treatment for OSA, but it has not been widely used due to poor compliance and other factors. The new hypoglycemic drug gliflozin is a sodium-glucose cotransporter 2 inhibitor, which has been used in the clinical treatment of diabetes, heart failure, chronic kidney disease and other diseases. In recent years, studies have suggested that SGLT-2i can benefit OSA patients. This author reviewed the research progress of gliflozin in the treatment of OSA.